Replies to post #250880 on Biotech Values

[DewDiligence]

B-I starts phase-1 trial_of triple-agonist peptide drug_for obesity:

https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/phase-1-start-novel-triple-agonist-obesity-treatment

This PR does not confirm—or deny—that the three targets are the same ones hit by LLY’s Retatrutide (#msg-173959895).

[DewDiligence]

NVO licenses “triple G” candidate from Chinese company:

https://www.globenewswire.com/news-release/2025/03/24/3047656/0/en/The-United-Laboratories-and-Novo-Nordisk-announce-exclusive-license-agreement-for-UBT251-a-GLP-1-GIP-glucagon-triple-receptor-agonist.html

The United Laboratories International Holdings Limited (TUL) and Novo Nordisk A/S today announced that Novo Nordisk and TUL’s wholly-owned subsidiary The United Bio-Technology (Hengqin) Co., Ltd. (United Biotechnology), have entered into an exclusive license agreement for UBT251, a triple agonist of the receptors for GLP-1, GIP, and glucagon in early-stage clinical development for the treatment of obesity, type 2 diabetes, and other diseases.

Under the license agreement, Novo Nordisk will obtain exclusive worldwide rights (excluding Chinese mainland, Hong Kong, Macau, and Taiwan) to develop, manufacture, and commercialize UBT251. United Biotechnology will retain the rights for UBT251 in Chinese mainland, Hong Kong, Macau, and Taiwan. United Biotechnology is eligible to receive an upfront payment of 200 million US dollars and potential milestone payments of up to 1.8 billion dollars from Novo Nordisk, as well as tiered royalties on net sales outside of Chinese mainland, Hong Kong, Macau, and Taiwan.

LLY has its own “triple G” drug candidate called Retatrutide (#msg-173959895), and B-I may have one too (#msg-174688818).

[DewDiligence]

LLY retatrutide—(a/k/a “3G”)—shows respectable weight loss—but high dropout rate—in phase-3 trial for osteoarthritis pain:

https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-weight-loss-of-up-to-an-average-of-71-2-lbs-along-with-substantial-relief-from-osteoarthritis-pain-in-first-successful-phase-3-trial-302638804.html

LLY is up slightly in the PM session.